ULTIMÉ
DEAD

Serial Number

79352105

Owner

AUSTRALIA BIOTECHNOLOGY GROUP PTY LTD

Filing Date

Jul 19, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ULTIMÉ Trademark

Serial Number: 79352105

ULTIMÉ is a trademark filed by AUSTRALIA BIOTECHNOLOGY GROUP PTY LTD on July 19, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

AUSTRALIA BIOTECHNOLOGY GROUP PTY LTD (3 trademarks)

Fy 1 272-284 Frankston-Dandenong Rd

Entity Type: 82

Trademark Details

Filing Date

July 19, 2022

Registration Date

Not Registered

Goods & Services

Antioxidants (dietary supplements); antibiotic food supplements for animals; nutritional supplements; vitamin supplements; vitamin supplements for animals; capsules for pharmaceutical purposes; eucalyptus for pharmaceutical purposes; flaxseed for pharmaceutical purposes; gallic acid for pharmaceutical purposes; lactose for pharmaceutical purposes; meal for pharmaceutical purposes; moisturising body lotion (pharmaceutical); moisturising creams (pharmaceutical); moisturising gels (pharmaceutical); moisturising lotions (pharmaceutical); moisturising skin creams (pharmaceutical); moisturising skin lotions (pharmaceutical); oils for pharmaceutical purposes; pain killers (pharmaceuticals); pharmaceutical compound eye-drops; pharmaceutical anticoagulant preparations; pharmaceutical appetite suppressants; pharmaceutical compositions; pharmaceutical creams; pharmaceutical cytostatic preparations; pharmaceutical cytostatic preparations for use in parenteral form; pharmaceutical drugs; pharmaceutical drugs being a positive inotropic agent; pharmaceutical lipsalves; pharmaceutical medicaments in unit dosage form; pharmaceutical preparations; pharmaceutical preparations being antacids; pharmaceutical preparations being antiulceratives; pharmaceutical preparations being hormone preparations for human use; pharmaceutical preparations containing a vasodilator; pharmaceutical preparations containing amino acids; pharmaceutical preparations containing calcitonin; pharmaceutical preparations containing coagulants; pharmaceutical preparations containing enzymes; pharmaceutical preparations containing essential oils; pharmaceutical preparations containing fish oil; pharmaceutical preparations containing fluoride for prevention of dental decay; pharmaceutical preparations containing hormones for humans; pharmaceutical preparations containing royal jelly; pharmaceutical preparations containing vitamins; pharmaceutical preparations for alleviating disorders of the brain; pharmaceutical preparations for animals; pharmaceutical preparations for application to the skin; pharmaceutical preparations for assisting the prevention of bone diseases; pharmaceutical preparations for enteral administration; pharmaceutical preparations for growing eyebrows; pharmaceutical preparations for growing eyelashes; pharmaceutical preparations for health care; pharmaceutical preparations for human use; pharmaceutical preparations for nasal use; pharmaceutical preparations for oral use; pharmaceutical preparations for personal use; pharmaceutical preparations for promoting the maturation of the cervix; pharmaceutical preparations for skin care; pharmaceutical preparations for the preservation and storage of human organs; pharmaceutical preparations for the prevention of bone conditions; pharmaceutical preparations for the prevention of cardiovascular disorders; pharmaceutical preparations for the relief of insect bites; pharmaceutical preparations for the relief of insect stings; pharmaceutical preparations for the therapeutic treatment of diabetes mellitus; pharmaceutical preparations for the topical treatment of dermatological disorders; pharmaceutical preparations for the treatment of alcoholism; pharmaceutical preparations for the treatment of blackheads; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of cardiovascular disorders; pharmaceutical preparations for the treatment of depressive illness; pharmaceutical preparations for the treatment of dermatological disorders; pharmaceutical preparations for the treatment of digestive maladies; pharmaceutical preparations for the treatment of disorders of the central nervous system; pharmaceutical preparations for the treatment of disorders of the gastro-enterological tract; pharmaceutical preparations for the treatment of dyslexia; pharmaceutical preparations for the treatment of gastric diseases; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for the treatment of gynaecological disorders; pharmaceutical preparations for the treatment of joint related diseases; pharmaceutical preparations for the treatment of pimples; pharmaceutical preparations for the treatment of premenstrual tension; pharmaceutical preparations for the treatment of psoriasis; pharmaceutical preparations for the treatment of psoriasis in human beings; pharmaceutical preparations for the treatment of spots; pharmaceutical preparations for the treatment of the eyes; pharmaceutical preparations for topical use; pharmaceutical preparations for treating dandruff; pharmaceutical preparations for treating sunburn; pharmaceutical preparations for use as laxative; pharmaceutical preparations for use in dentistry; pharmaceutical preparations for use in discouraging the smoking habit; pharmaceutical preparations for use in gynaecology; pharmaceutical preparations for use in hypercholesterolemia therapy; pharmaceutical preparations for use in the treatment of arthritis; pharmaceutical preparations for use in the treatment of arthrosis; pharmaceutical preparations for use in the treatment of colostomy patients; pharmaceutical preparations for use in the treatment of diseases of the vertebral column; pharmaceutical preparations for use in the treatment of hormonal disorders; pharmaceutical preparations for use in the treatment of ileostomy patients; pharmaceutical preparations for use in the treatment of lumbago; pharmaceutical preparations for use in the treatment of muscle tension; pharmaceutical preparations for use in the treatment of pimples; pharmaceutical preparations for use in the treatment of rheumatism; pharmaceutical tablets; pharmaceutical sweets; pharmaceutical substances; plant extracts for pharmaceutical purposes; plant extracts for pharmaceutical use; pharmaceutical tonic preparations; propolis for pharmaceutical purposes; skincare preparations (pharmaceutical); sprays for use on the body (pharmaceuticals); yeast extracts for pharmaceutical purposes; yeast for pharmaceutical purposes

Filing History

FINAL DISPOSITION NOTICE SENT TO IB
Jan 4, 2025 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 4, 2025 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 1, 2024 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 13, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 13, 2024 OPNR
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Jan 3, 2024 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Jan 3, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jan 3, 2024 ABN2
REFUSAL PROCESSED BY IB
Jul 10, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 17, 2023 RFCS
REFUSAL PROCESSED BY MPU
Jun 17, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 9, 2023 RFCR
NON-FINAL ACTION WRITTEN
May 8, 2023 CNRT
ASSIGNED TO EXAMINER
May 4, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 18, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 14, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 13, 2022 REPR